BioStock Studio: Aptahem's CEO on upcoming milestones

Aptahem has taken several steps forward in 2022. Recently, the biotech company passed a milestone with the start of the clinical phase I study with the sepsis candidate Apta-1. CEO Mikael Lindstam visited BioStock's studio at Medicon Village in Lund to present the company and answer questions about the rights issue that is currently underway.

Watch the presentation and interview with Aptahem's CEO Mikael Lindstam at biostock.se:

https://www.biostock.se/en/2022/11/aptahems-ceo-on-upcoming-milestones/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/